ReviewOncotarget2018
Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2020Pooled it
- LMO1 polymorphisms and the risk of neuroblastoma: Assessment of meta-analysis of case-control studies.Journal of cellular and molecular medicine · 2020Pooled it
- Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes.BMC cancer · 2025Article
- Variation in the co-expression profile highlights a loss of miRNA-mRNA regulation in multiple cancer types.Non-coding RNA research · 2022Article
- Comparison of Physicochemical, Mechanical, and (Micro-)Biological Properties of Sintered Scaffolds Based on Natural- and Synthetic Hydroxyapatite Supplemented with Selected Dopants.International journal of molecular sciences · 2022Article
- Protein signatures to distinguish aggressive from indolent prostate cancer.The Prostate · 2022Article
- [Pregnane X receptor promotes programmed cell death protein 4 expression in HepG2 cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank.Frontiers in oncology · 2019Article
- Association betweenMolecular biology research communications · 2018Article
- Protective effect of menthol against diethylnitrosamine-induced hepatocellular carcinoma in mice by downregulatingAvicenna journal of phytomedicineArticle
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70-0.96,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.